Krystal Biotech (KRYS) Revenue & Revenue Breakdown
Krystal Biotech Revenue Highlights
Latest Revenue (Y)
$389.13M
Latest Revenue (Q)
$119.22M
Krystal Biotech Revenue by Period
Krystal Biotech Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $389.13M | 33.94% |
| 2024-12-31 | $290.51M | 473.02% |
| 2023-12-31 | $50.70M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2018-12-31 | $1.03M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Krystal Biotech generated $389.13M in revenue during NA 2025, up 33.94% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Krystal Biotech Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | $119.22M | 2.46% |
| 2026-03-31 | $116.36M | 8.64% |
| 2025-12-31 | $107.11M | 9.51% |
| 2025-09-30 | $97.80M | 1.83% |
| 2025-06-30 | $96.04M | 8.91% |
| 2025-03-31 | $88.18M | -3.24% |
| 2024-12-31 | $91.14M | 8.70% |
| 2024-09-30 | $83.84M | 19.29% |
| 2024-06-30 | $70.28M | 55.32% |
| 2024-03-31 | $45.25M | 7.37% |
| 2023-12-31 | $42.14M | 392.55% |
| 2023-09-30 | $8.56M | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | -100.00% |
| 2019-06-30 | $542.00K | -7.03% |
| 2019-03-31 | $583.00K | -43.23% |
| 2018-12-31 | $1.03M | 373.27% |
| 2018-09-30 | $217.00K | 25.43% |
| 2018-06-30 | $173.00K | 36.22% |
| 2018-03-31 | $127.00K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | - |
Krystal Biotech generated $119.22M in revenue during Q2 2026, up 2.46% compared to the previous quarter, and up 135.20% compared to the same period a year ago.
Krystal Biotech Revenue Breakdown
Krystal Biotech Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Jun 26 | Mar 26 |
|---|---|---|
| Europe | $19.28M | $20.68M |
| JAPAN | $8.31M | $8.19M |
| UNITED STATES | $91.63M | $87.49M |
Latest
Krystal Biotech's latest quarterly revenue breakdown by geography, as of Jun 26: UNITED STATES (76.86%), Europe (16.17%), and JAPAN (6.97%).
Krystal Biotech Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TFX | Teleflex | $1.99B | $570.33M |
| PTCT | PTC Therapeutics | $1.73B | $360.52M |
| ALKS | Alkermes | $1.48B | $496.01M |
| ARWR | Arrowhead Pharmaceuticals | $829.45M | $75.25M |
| TGTX | TG Therapeutics | $616.29M | $240.34M |
| KRYS | Krystal Biotech | $389.13M | $119.22M |
| CRSP | CRISPR Therapeutics | $3.51M | $10.18M |
| PTGX | Protagonist Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| MTSR | Metsera | - | - |